
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Dive Brief: Novartis’ radiopharmaceutical drug Pluvicto can now be used much more widely to treat men with a type of metastatic prostate cancer after U.S. regulators on Friday cleared the medicine for use before chemotherapy. Specifically, Pluvicto can …